Amedeo Smart

Free Medical Literature Service


 

Amedeo

Dermatology

  Free Subscription

Articles published in
Lancet
    September 2021
  1. CARLINO MS, Larkin J, Long GV
    Immune checkpoint inhibitors in melanoma.
    Lancet. 2021;398:1002-1014.
    >> Share

    July 2021
  2. CORTES J, Rugo HS, Guo Z, Karantza V, et al
    Pembrolizumab plus chemotherapy in triple-negative breast cancer - Authors' reply.
    Lancet. 2021;398:24-25.
    >> Share

  3. MASUDA J, Ozaki Y, Hara F, Kitano S, et al
    Pembrolizumab plus chemotherapy in triple-negative breast cancer.
    Lancet. 2021;398:24.
    >> Share

    May 2021
  4. REICH K, Teixeira HD, de Bruin-Weller M, Bieber T, et al
    Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet. 2021 May 20. pii: S0140-6736(21)00589.
    >> Share

  5. GUTTMAN-YASSKY E, Teixeira HD, Simpson EL, Papp KA, et al
    Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.
    Lancet. 2021 May 20. pii: S0140-6736(21)00588.
    >> Share

  6. THYSSEN JP, Thomsen SF
    Treatment of atopic dermatitis with biologics and Janus kinase inhibitors.
    Lancet. 2021 May 20. pii: S0140-6736(21)00717.
    >> Share

    April 2021
  7. RUBEL D
    Nanobody cytokine blockers in psoriasis.
    Lancet. 2021;397:1523-1524.
    >> Share

  8. PAPP KA, Weinberg MA, Morris A, Reich K, et al
    IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study.
    Lancet. 2021;397:1564-1575.
    >> Share

  9. GRIFFITHS CEM, Armstrong AW, Gudjonsson JE, Barker JNWN, et al
    Psoriasis.
    Lancet. 2021;397:1301-1315.
    >> Share

    February 2021
  10. LAMBRECHTS RA, Uyttenboogaart M, Drost G
    A vertebral artery halo sign indicates giant cell arteritis affecting the posterior circulation of the brain.
    Lancet. 2021;397:e6.
    >> Share

  11. LANGLEY RE, Gilbert DC, Duong T, Clarke NW, et al
    Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme.
    Lancet. 2021;397:581-591.
    >> Share

  12. REICH K, Papp KA, Blauvelt A, Langley RG, et al
    Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
    Lancet. 2021;397:487-498.
    >> Share

  13. GORDON KB, Foley P, Krueger JG, Pinter A, et al
    Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.
    Lancet. 2021;397:475-486.
    >> Share

  14. HUANG WW, Feldman SR
    The next quantum leap forward? Bimekizumab for psoriasis.
    Lancet. 2021;397:446-448.
    >> Share

    January 2021
  15. HUDOWENZ O, Klemm P, Lange U, Mueller-Ladner U, et al
    Widespread soft tissue calcification in systemic sclerosis, polymyositis, and polyarthritis.
    Lancet. 2021;397:409.
    >> Share

  16. GHORESCHI K, Balato A, Enerback C, Sabat R, et al
    Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis.
    Lancet. 2021 Jan 27. pii: S0140-6736(21)00184.
    >> Share

  17. CHEN L, Zhou M
    Must be sympathetic nervous system with unilateral facial flushing in harlequin syndrome.
    Lancet. 2021;397:318.
    >> Share

  18. SIMPSON EL, Bieber T, Thyssen JP, Valdez H, et al
    Abrocitinib for atopic dermatitis - Authors' reply.
    Lancet. 2021;397:196.
    >> Share

  19. UPPAL SK, Chat VS, Kearns DG, Wu JJ, et al
    Abrocitinib for atopic dermatitis.
    Lancet. 2021;397:195-196.
    >> Share

  20. CHAKRABORTY U, Chandra A
    Bitot's spots, dry eyes, and night blindness indicate vitamin A deficiency.
    Lancet. 2021;397:e2.
    >> Share

    December 2020
  21. LLEO A, Wang GQ, Gershwin ME, Hirschfield GM, et al
    Primary biliary cholangitis.
    Lancet. 2020;396:1915-1926.
    >> Share

  22. LAI VWY, Meher-Homji Z, Liu F, Sasadeusz J, et al
    Primary herpes simplex virus type 2 hepatitis diagnosed during laparoscopy.
    Lancet. 2020;396:e90.
    >> Share

  23. CORTES J, Cescon DW, Rugo HS, Nowecki Z, et al
    Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
    Lancet. 2020;396:1817-1828.
    >> Share

    November 2020
  24. ROSMARIN D, Butler K, Kuo F, Harris JE, et al
    Ruxolitinib cream for the treatment of vitiligo - Authors' reply.
    Lancet. 2020;396:1736.
    >> Share

  25. UPPAL SK, Kearns DG, Chat VS, Wu JJ, et al
    Ruxolitinib cream for the treatment of vitiligo.
    Lancet. 2020;396:1735-1736.
    >> Share

  26. MCCLELLAND S 3RD
    Breast cancer radiation therapy.
    Lancet. 2020;396:1559.
    >> Share

  27. BRUNT AM, Haviland JS, Wheatley DA, Yarnold JR, et al
    Breast cancer radiation therapy - Authors' reply.
    Lancet. 2020;396:1559-1560.
    >> Share

  28. OFFERSEN BV, Overgaard J
    Breast cancer radiation therapy.
    Lancet. 2020;396:1558.
    >> Share

  29. DOUEK M, De Silva-Minor S, Davies L, Jones B, et al
    Breast cancer radiation therapy.
    Lancet. 2020;396:1558-1559.
    >> Share

    October 2020
  30. UDOMKARNJANANUN S, Puapatanakul P, Praditpornsilpa K
    Relapsing polychondritis associated with pauci-immune crescentic glomerulonephritis.
    Lancet. 2020;396:e63.
    >> Share

    September 2020
  31. OZPOLAT HT, Baran B, Akyuz F
    Skin lesions indicate cause of acute gastrointestinal bleeding: neurofibromatosis type 1.
    Lancet. 2020;396:e52.
    >> Share

  32. STERGIOU IE, Christoforou P, Sypsa G, Skoufias S, et al
    Extraordinary extrahaematological manifestations of chronic myelomonocytic leukaemia.
    Lancet. 2020;396:853.
    >> Share

  33. DI COSIMO S
    Advancing immunotherapy for early-stage triple-negative breast cancer.
    Lancet. 2020 Sep 18. pii: S0140-6736(20)31962.
    >> Share

  34. MITTENDORF EA, Zhang H, Barrios CH, Saji S, et al
    Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3
    Lancet. 2020 Sep 18. pii: S0140-6736(20)31953.
    >> Share

  35. ABIGNANO G, Mennillo GA, Lettieri G
    Foot ulcers in systemic sclerosis escape surgical amputation.
    Lancet. 2020;396:e29.
    >> Share

    August 2020
  36. CARDENAS-DE LA GARZA JA, Esquivel-Valerio JA, Arvizu-Rivera RI, Colunga-Pedraza PR, et al
    Flushing out a plasmacytoma in a patient with POEMS and AESOP syndromes.
    Lancet. 2020;396:e21.
    >> Share

  37. FREITAS PFS, Oliveira JM, Kater CE
    Crisis? What crisis? Abdominal pain and darkening skin in Addison's disease.
    Lancet. 2020;396:498.
    >> Share

  38. JAMIOLKOWSKI D, Muhleisen B, Muller S, Navarini AA, et al
    SARS-CoV-2 PCR testing of skin for COVID-19 diagnostics: a case report.
    Lancet. 2020 Aug 13. pii: S0140-6736(20)31754.
    >> Share

  39. LANGAN SM, Irvine AD, Weidinger S
    Atopic dermatitis.
    Lancet. 2020;396:345-360.
    >> Share

    July 2020
  40. SIMPSON EL, Sinclair R, Forman S, Wollenberg A, et al
    Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
    Lancet. 2020;396:255-266.
    >> Share

  41. WEIDINGER S, Schreiber S
    Abrocitinib for atopic dermatitis: a step forward.
    Lancet. 2020;396:215-217.
    >> Share

  42. OBASI AI
    Equity in excellence or just another tax on Black skin?
    Lancet. 2020 Jul 23. pii: S0140-6736(20)31536.
    >> Share

  43. LAM RPK, Wong KW, Wan CK
    Allergic contact dermatitis and tracheobronchitis associated with repeated exposure to tear gas.
    Lancet. 2020 Jul 13. pii: S0140-6736(20)31560.
    >> Share

  44. PASSERON T
    First step in a new era for treatment of patients with vitiligo.
    Lancet. 2020;396:74-75.
    >> Share

  45. ROSMARIN D, Pandya AG, Lebwohl M, Grimes P, et al
    Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial.
    Lancet. 2020;396:110-120.
    >> Share

  46. SHAIGANY S, Gnirke M, Guttmann A, Chong H, et al
    An adult with Kawasaki-like multisystem inflammatory syndrome associated with COVID-19.
    Lancet. 2020 Jul 10. pii: S0140-6736(20)31526.
    >> Share

  47. GINSBURG O, Horton R
    A Lancet Commission on women and cancer.
    Lancet. 2020;396:11-13.
    >> Share

    June 2020
  48. ALLEN S, Cortina CS
    An unusual cause of breast hypertrophy: pseudoangiomatous stromal hyperplasia secondary to contraceptive implant.
    Lancet. 2020;395:1937.
    >> Share

  49. GUTZMER R, Stroyakovskiy D, Gogas H, Robert C, et al
    Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet. 2020;395:1835-1844.
    >> Share

  50. RIBAS A
    Triple therapy for BRAF(V600)-mutated melanoma.
    Lancet. 2020;395:1814-1815.
    >> Share

  51. AHMED MA, Abdelnabi M, Almaghraby A, Elkafrawy FR, et al
    Neuropathy, encephalopathy, status epilepticus, and acute intermittent porphyria.
    Lancet. 2020;395:e101.
    >> Share

    May 2020
  52. MURRAY BRUNT A, Haviland JS, Wheatley DA, Sydenham MA, et al
    Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial.
    Lancet. 2020;395:1613-1626.
    >> Share

  53. ZIMMER L, Livingstone E, Hassel JC, Fluck M, et al
    Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Lancet. 2020;395:1558-1568.
    >> Share

  54. SULLIVAN RJ
    Adjuvant nivolumab plus ipilimumab for resected stage IV melanoma.
    Lancet. 2020;395:1524-1525.
    >> Share

  55. VERDONI L, Mazza A, Gervasoni A, Martelli L, et al
    An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study.
    Lancet. 2020 May 13. pii: S0140-6736(20)31103.
    >> Share

  56. HETLAND ML
    Psoriatic arthritis: still room for improvement.
    Lancet. 2020;395:1463-1465.
    >> Share

  57. MCINNES IB, Behrens F, Mease PJ, Kavanaugh A, et al
    Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.
    Lancet. 2020;395:1496-1505.
    >> Share

    April 2020
  58. JOHNSON PDR
    Buruli ulcer: cured by 8 weeks of oral antibiotics?
    Lancet. 2020;395:1231-1232.
    >> Share

  59. PHILLIPS RO, Robert J, Abass KM, Thompson W, et al
    Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial.
    Lancet. 2020;395:1259-1267.
    >> Share

  60. KERSCHBAUMER A, Aletaha D
    Targeting p19 in psoriatic arthritis: more than just another therapeutic approach?
    Lancet. 2020;395:1091-1093.
    >> Share

  61. MEASE PJ, Rahman P, Gottlieb AB, Kollmeier AP, et al
    Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial.
    Lancet. 2020;395:1126-1136.
    >> Share

  62. DEODHAR A, Helliwell PS, Boehncke WH, Kollmeier AP, et al
    Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFalpha inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial.
    Lancet. 2020;395:1115-1125.
    >> Share

    March 2020
  63. BOUJAN N, Geraud C
    Neuropsychiatric symptoms, skin disease, and weight loss: necrolytic migratory erythema and a glucagonoma.
    Lancet. 2020;395:985.
    >> Share

  64. SPRING LM, Wander SA, Andre F, Moy B, et al
    Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future.
    Lancet. 2020;395:817-827.
    >> Share

  65. KROWN SE, Moser CB, MacPhail P, Matining RM, et al
    Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial.
    Lancet. 2020 Mar 5. pii: S0140-6736(19)33222.
    >> Share

  66. FREEMAN EE, McMahon DE, Laker-Oketta M
    Time to address disparities in the standard of care for Kaposi sarcoma.
    Lancet. 2020 Mar 5. pii: S0140-6736(20)30473.
    >> Share

    February 2020
  67. DESGRANGES F, Coste AT, Wernly D, Dufour J, et al
    Immunosuppressed gardener pricked by roses grows Legionella longbeachae.
    Lancet. 2020;395:604.
    >> Share

  68. PERRETT KP, Peters RL
    Emollients for prevention of atopic dermatitis in infancy.
    Lancet. 2020 Feb 19. pii: S0140-6736(19)33174.
    >> Share

  69. SKJERVEN HO, Rehbinder EM, Vettukattil R, LeBlanc M, et al
    Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial.
    Lancet. 2020 Feb 19. pii: S0140-6736(19)32983.
    >> Share

  70. CHALMERS JR, Haines RH, Bradshaw LE, Montgomery AA, et al
    Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial.
    Lancet. 2020 Feb 19. pii: S0140-6736(19)32984.
    >> Share

  71. EARL HM, Hiller L, Plummer C, Miles D, et al
    Protective strategies to prevent trastuzumab-induced cardiotoxicity - Authors' reply.
    Lancet. 2020;395:492-493.
    >> Share

  72. GUO S, Tse G, Liu T
    Protective strategies to prevent trastuzumab-induced cardiotoxicity.
    Lancet. 2020;395:491-492.
    >> Share

  73. NASH P
    Inhibition of interleukins 17A and 17F in psoriatic arthritis.
    Lancet. 2020;395:395-396.
    >> Share

  74. LANE R
    Geraldine McGinty: leading light in US radiology.
    Lancet. 2020;395:407.
    >> Share

  75. RITCHLIN CT, Kavanaugh A, Merola JF, Schett G, et al
    Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial.
    Lancet. 2020;395:427-440.
    >> Share

    January 2020
  76. CHUMSRI S, Thompson EA
    Carryover effects of aromatase inhibitors in prevention.
    Lancet. 2020;395:91-92.
    >> Share

  77. THE LANCET
    Biosimilars: a new era in access to breast cancer treatment.
    Lancet. 2020;395:2.
    >> Share

    December 2019
  78. COLES CE, Bliss JM, Poortmans PM
    Accelerated partial breast irradiation: more questions than answers?
    Lancet. 2019;394:2127-2129.
    >> Share

  79. CUZICK J, Sestak I, Forbes JF, Dowsett M, et al
    Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial.
    Lancet. 2019 Dec 11. pii: S0140-6736(19)32955.
    >> Share

  80. STIENSTRA Y, Beeres DT, Phillips R, Vonk M, et al
    The public health control of scabies: priorities for research and action.
    Lancet. 2019;394:2068.
    >> Share

  81. MIDDLETON J, Walker SL, House T, Head MG, et al
    Ivermectin for the control of scabies outbreaks in the UK.
    Lancet. 2019;394:2068-2069.
    >> Share

  82. VICINI FA, Cecchini RS, White JR, Arthur DW, et al
    Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial.
    Lancet. 2019 Dec 5. pii: S0140-6736(19)32514.
    >> Share

  83. WHELAN TJ, Julian JA, Berrang TS, Kim DH, et al
    External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial.
    Lancet. 2019 Dec 5. pii: S0140-6736(19)32515.
    >> Share

    October 2019
  84. THANGARAJU P, Venkatesan S
    A double blow for a patient with leprosy: a reversal reaction and an adverse drug reaction.
    Lancet. 2019;394:1450.
    >> Share

  85. ABDALLAH FW, Wijeysundera DN
    Anaesthetic interventions and long-term tumour recurrence.
    Lancet. 2019 Oct 18. pii: S0140-6736(19)32314.
    >> Share

  86. SESSLER DI, Pei L, Huang Y, Fleischmann E, et al
    Recurrence of breast cancer after regional or general anaesthesia: a randomised controlled trial.
    Lancet. 2019 Oct 18. pii: S0140-6736(19)32313.
    >> Share

  87. BRUINSTROOP E, Cairo I, Drillenburg P, van Dam PS, et al
    Hypothyroidism to Graves' disease and late appearance of pretibial myxoedema.
    Lancet. 2019;394:1364.
    >> Share

    September 2019
  88. SCHMIDT E, Kasperkiewicz M, Joly P
    Pemphigus.
    Lancet. 2019;394:882-894.
    >> Share

  89. CHAYED Z, Kamaleswaran S, Bygum A
    A spot diagnosis! Aplasia cutis congenita in monozygotic twins.
    Lancet. 2019;394:868.
    >> Share

    August 2019
  90. BERAL V, Peto R, Pirie K, Reeves G, et al
    Menopausal hormone therapy and 20-year breast cancer mortality.
    Lancet. 2019 Aug 29. pii: S0140-6736(19)32033.
    >> Share


  91. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence.
    Lancet. 2019 Aug 29. pii: S0140-6736(19)31709.
    >> Share

  92. KOTSOPOULOS J
    Menopausal hormones: definitive evidence for breast cancer.
    Lancet. 2019 Aug 29. pii: S0140-6736(19)31901.
    >> Share

  93. NAKKAZI E
    People with albinism in Africa: contending with skin cancer.
    Lancet. 2019;394:553-554.
    >> Share

  94. REICH K, Armstrong AW, Langley RG, Flavin S, et al
    Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
    Lancet. 2019 Aug 8. pii: S0140-6736(19)31773.
    >> Share

  95. MAHIL SK, Smith CH
    Psoriasis biologics: a new era of choice.
    Lancet. 2019 Aug 8. pii: S0140-6736(19)31772.
    >> Share

  96. CHAPPELL LC, Bell JL, Smith A, Linsell L, et al
    Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial.
    Lancet. 2019 Aug 1. pii: S0140-6736(19)31270.
    >> Share

    July 2019
  97. ENGELMAN D, Cantey PT, Marks M, Solomon AW, et al
    The public health control of scabies: priorities for research and action.
    Lancet. 2019;394:81-92.
    >> Share

  98. THOMPSON JF, Friedman EB
    Appropriate excision margins for cutaneous melanomas.
    Lancet. 2019 Jul 4. pii: S0140-6736(19)31272.
    >> Share

  99. LEBWOHL M
    Interleukin-23 blockade: another breakthrough in the treatment of psoriasis.
    Lancet. 2019 Jul 4. pii: S0140-6736(19)31513.
    >> Share

  100. REICH K, Gooderham M, Thaci D, Crowley JJ, et al
    Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial.
    Lancet. 2019 Jul 4. pii: S0140-6736(19)30952.
    >> Share

  101. UTJES D, Malmstedt J, Teras J, Drzewiecki K, et al
    2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: long-term follow-up of a multicentre, randomised trial.
    Lancet. 2019 Jul 4. pii: S0140-6736(19)31132.
    >> Share

    June 2019
  102. HURVITZ SA
    Is the duration of adjuvant trastuzumab debate still clinically relevant?
    Lancet. 2019;393:2565-2567.
    >> Share

  103. DROLET M, Benard E, Perez N, Brisson M, et al
    Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis.
    Lancet. 2019 Jun 26. pii: S0140-6736(19)30298.
    >> Share

  104. QIAN YT, Ma DL
    Atypical presentation of classic Kaposi's sarcoma.
    Lancet. 2019;393:2521.
    >> Share

  105. PIVOT X, Romieu G, Debled M, Pierga JY, et al
    6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial.
    Lancet. 2019 Jun 6. pii: S0140-6736(19)30653.
    >> Share

  106. EARL HM, Hiller L, Vallier AL, Loi S, et al
    6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.
    Lancet. 2019 Jun 6. pii: S0140-6736(19)30650.
    >> Share

    March 2019
  107. MCCRINDLE BW, Rowley AH
    Improving coronary artery outcomes for children with Kawasaki disease.
    Lancet. 2019 Mar 7. pii: S0140-6736(18)33133.
    >> Share

  108. HAMADA H, Suzuki H, Onouchi Y, Ebata R, et al
    Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised
    Lancet. 2019 Mar 7. pii: S0140-6736(18)32003.
    >> Share

  109. ABDOLI A
    Leishmaniasis.
    Lancet. 2019;393:872.
    >> Share

  110. BURZA S, Croft SL, Boelaert M
    Leishmaniasis - Authors' reply.
    Lancet. 2019;393:872-873.
    >> Share

  111. DEPAQUIT J, Gay F, Kaltenbach ML
    Leishmaniasis.
    Lancet. 2019;393:871-872.
    >> Share

  112. SAURABH S
    Leishmaniasis.
    Lancet. 2019;393:871.
    >> Share

    February 2019
  113. MUTEBI M
    Africa rising: gendered journeys of women patients and providers.
    Lancet. 2019;393:517-518.
    >> Share

  114. HURVITZ SA
    Dose intensification of chemotherapy for early breast cancer in the age of de-escalation.
    Lancet. 2019 Feb 7. pii: S0140-6736(19)30197.
    >> Share


  115. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials.
    Lancet. 2019 Feb 7. pii: S0140-6736(18)33137.
    >> Share

  116. MOSE KF, Bygum A
    Chinese herbal remedy found to contain steroids and antifungals.
    Lancet. 2019;393:446.
    >> Share

    January 2019
  117. GILHAR A, Keren A, Paus R
    JAK inhibitors and alopecia areata.
    Lancet. 2019;393:318-319.
    >> Share

  118. POWER SP, O'Mahony D
    Diffuse large vessel giant cell arteritis found by (18)Fluorodeoxyglucose PET/CT imaging.
    Lancet. 2019;393:349.
    >> Share

    December 2018
  119. CAMERON DA, Gelber RD, Procter M, Suter T, et al
    Concerns about cardiotoxicity in the HERA trial - Authors' reply.
    Lancet. 2018;390:2767-2768.
    >> Share

  120. LEVY A, Chargari C, Deutsch E, Rivera S, et al
    Concerns about cardiotoxicity in the HERA trial.
    Lancet. 2018;390:2767.
    >> Share

  121. MEASE P, Coates LC, Helliwell PS, Stanislavchuk M, et al
    Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial.
    Lancet. 2018;392:2367-2377.
    >> Share

    October 2018
  122. MAYA Y, Tashimo A, Ota M
    Persistent red and swollen eyelids.
    Lancet. 2018;392:1552.
    >> Share

  123. COSTEDOAT-CHALUMEAU N, Houssiau FA
    Ustekinumab: a promising new drug for SLE?
    Lancet. 2018;392:1284-1286.
    >> Share

  124. BOUSSINESQ M
    A new powerful drug to combat river blindness.
    Lancet. 2018;392:1170-1172.
    >> Share

  125. OPOKU NO, Bakajika DK, Kanza EM, Howard H, et al
    Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial.
    Lancet. 2018;392:1207-1216.
    >> Share

    September 2018
  126. SCHADENDORF D, van Akkooi ACJ, Berking C, Griewank KG, et al
    Melanoma.
    Lancet. 2018;392:971-984.
    >> Share

  127. LEBWOHL B, Sanders DS, Green PH
    Coeliac disease and dermatitis herpetiformis - Authors' reply.
    Lancet. 2018;392:917.
    >> Share

  128. RODRIGUES F, Bachmeyer C
    Coeliac disease and dermatitis herpetiformis.
    Lancet. 2018;392:916.
    >> Share

  129. CAIO G, De Giorgio R, Volta U
    Coeliac disease and dermatitis herpetiformis.
    Lancet. 2018;392:916-917.
    >> Share

  130. JANARTHANAN M, Rathinasamy J
    Aortic calcification in longstanding, undiagnosed Takayasu arteritis.
    Lancet. 2018;392:950.
    >> Share

    August 2018
  131. LA PLACA M, Chessa MA
    Erythema multiforme major with swollen lips and crusted erosions.
    Lancet. 2018;392:592.
    >> Share

  132. BURZA S, Croft SL, Boelaert M
    Leishmaniasis.
    Lancet. 2018 Aug 17. pii: S0140-6736(18)31204.
    >> Share

  133. WILLER H
    Breast cancer in Venezuela: back to the 20th century.
    Lancet. 2018;392:461-462.
    >> Share

  134. CLINE A, Feldman SR
    Risankizumab for psoriasis.
    Lancet. 2018 Aug 7. pii: S0140-6736(18)31781.
    >> Share

  135. GORDON KB, Strober B, Lebwohl M, Augustin M, et al
    Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
    Lancet. 2018 Aug 7. pii: S0140-6736(18)31713.
    >> Share

    July 2018
  136. WALLACE DJ, Furie RA, Tanaka Y, Kalunian KC, et al
    Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.
    Lancet. 2018;392:222-231.
    >> Share

    June 2018
  137. LIU XK, Li J
    Acral lentiginous melanoma.
    Lancet. 2018;391:e21.
    >> Share

  138. SHEIKH S, Sasieni P
    When should the errors in the UK's breast screening programme have been spotted?
    Lancet. 2018;391:2319-2320.
    >> Share

  139. DEODHAR A, Gottlieb AB, Boehncke WH, Dong B, et al
    Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study.
    Lancet. 2018;391:2213-2224.
    >> Share

  140. NASH P
    Psoriatic arthritis: novel targets add to a therapeutic renaissance.
    Lancet. 2018;391:2187-2189.
    >> Share

  141. THE LANCET
    Psoriatic arthritis: classification and holistic management.
    Lancet. 2018;391:2185.
    >> Share

  142. VAN DEN BOSCH F, Coates L
    Clinical management of psoriatic arthritis.
    Lancet. 2018;391:2285-2294.
    >> Share

  143. VEALE DJ, Fearon U
    The pathogenesis of psoriatic arthritis.
    Lancet. 2018;391:2273-2284.
    >> Share

  144. ZOU Y, Hu W, Zheng J, Pan M, et al
    Nail infestation: an atypical presentation of typical scabies.
    Lancet. 2018;391:2272.
    >> Share

    April 2018
  145. MITJA O, Godornes C, Houinei W, Kapa A, et al
    Re-emergence of yaws after single mass azithromycin treatment followed by targeted treatment: a longitudinal study.
    Lancet. 2018;391:1599-1607.
    >> Share

  146. RIEDL MA, Relan A, Harper JR, Cicardi M, et al
    C1 esterase inhibitor concentrates and attenuated androgens - Authors' reply.
    Lancet. 2018;391:1356.
    >> Share

  147. MULLER YD, Harr T, Dayer E, Seebach JD, et al
    C1 esterase inhibitor concentrates and attenuated androgens.
    Lancet. 2018;391:1355-1356.
    >> Share

    February 2018
  148. SMAJS D, Pospisilova P
    Macrolide resistance in yaws.
    Lancet. 2018 Feb 7. pii: S0140-6736(18)30205.
    >> Share

    January 2018
  149. VAIDYA JS, Bulsara M, Wenz F, Tobias JS, et al
    Targeted radiotherapy for early breast cancer.
    Lancet. 2018;391:26-27.
    >> Share

    October 2017
  150. AERTS O, Herman A, Bruze M, Goossens A, et al
    FreeStyle Libre: contact irritation versus contact allergy.
    Lancet. 2017;390:1644.
    >> Share

    July 2017
  151. SCHMITT AR, Wetter DA, Camilleri MJ, Khan SP, et al
    Langerhans cell histiocytosis presenting as a blueberry muffin rash.
    Lancet. 2017;390:155.
    >> Share

    June 2017
  152. MEASE P
    New pathways of treatment for psoriatic arthritis.
    Lancet. 2017;389:2268-2270.
    >> Share

    February 2017
  153. SPECHT JM, Davidson NE
    Optimal duration of trastuzumab for early HER2-positive breast cancer.
    Lancet. 2017 Feb 16. pii: S0140-6736(17)30322.
    >> Share

  154. CAMERON D, Piccart-Gebhart MJ, Gelber RD, Procter M, et al
    11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.
    Lancet. 2017 Feb 16. pii: S0140-6736(16)32616.
    >> Share

  155. PARES A
    An appealing new agent for treating cholestatic pruritus.
    Lancet. 2017 Feb 7. pii: S0140-6736(17)30320.
    >> Share

  156. HEGADE VS, Kendrick SF, Dobbins RL, Miller SR, et al
    Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study.
    Lancet. 2017 Feb 7. pii: S0140-6736(17)30319.
    >> Share

    December 2016
  157. NATSUME O, Kabashima S, Nakazato J, Yamamoto-Hanada K, et al
    Two-step egg introduction for prevention of egg allergy in high-risk infants with eczema (PETIT): a randomised, double-blind, placebo-controlled trial.
    Lancet. 2016 Dec 7. pii: S0140-6736(16)31418.
    >> Share

    November 2016
  158. HARBECK N, Gnant M
    Breast cancer.
    Lancet. 2016 Nov 16. pii: S0140-6736(16)31891.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016